The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population

Shen, Mo; Chen, Wei; Yu, Kai-yuan; Chen, Zhanguo; Wu, Zhou; Lin, Xiao; Weng, Zhiliang; Li, Chengdi; Wu, Ximei; Tao, Zhihua

doi:10.1016/j.yexmp.2010.10.009

Cited by 26 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the future, cancer screening programs with better accuracy and cost-efficiency may be implemented more widely by combining PSA with urinary biomarker(s), e.g. prostate cancer antigen 3 (PCA3)[8],[9], but is currently not officially recommended and the cost of the test is not always reimbursed to all men worldwide.…”

Section: Reported Incidence and Prostate-specific Antigen Screeningmentioning

confidence: 99%

East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians

Kimura¹

2012

Chin J Cancer

113

View full text Add to dashboard Cite

Prostate cancer is the most prevalent cancer in males in Western countries. The reported incidence in Asia is much lower than that in African Americans and European Caucasians. Although the lack of systematic prostate cancer screening system in Asian countries explains part of the difference, this alone cannot fully explain the lower incidence in Asian immigrants in the United States and west-European countries compared to the black and non-Hispanic white in those countries, nor the somewhat better prognosis in Asian immigrants with prostate cancer in the United States. Soy food consumption, more popular in Asian populations, is associated with a 25% to 30% reduced risk of prostate cancer. Prostate-specific antigen (PSA) is the only established and routinely implemented clinical biomarker for prostate cancer detection and disease status. Other biomarkers, such as urinary prostate cancer antigen 3 RNA, may increase accuracy of prostate cancer screening compared to PSA alone. Several susceptible loci have been identified in genetic linkage analyses in populations of countries in the West, and approximately 30 genetic polymorphisms have been reported to modestly increase the prostate cancer risk in genome-wide association studies. Most of the identified polymorphisms are reproducible regardless of ethnicity. Somatic mutations in the genomes of prostate tumors have been repeatedly reported to include deletion and gain of the 8p and 8q chromosomal regions, respectively; epigenetic gene silencing of glutathione S-transferase Pi (GSTP1); as well as mutations in androgen receptor gene. However, the molecular mechanisms underlying carcinogenesis, aggressiveness, and prognosis of prostate cancer remain largely unknown. Gene-gene and/or gene-environment interactions still need to be learned. In this review, the differences in PSA screening practice, reported incidence and prognosis of prostate cancer, and genetic factors between the populations in East and West factors are discussed.

show abstract

Section: Reported Incidence and Prostate-specific Antigen Screeningmentioning

confidence: 99%

East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians

Kimura¹

2012

Chin J Cancer

113

View full text Add to dashboard Cite

show abstract

“…For example, Differential display code 3 (DD3 PCA3 ), a prostate-specific lncRNA, appears to be a marker for early diagnosis of prostate cancer [4]. More important, DD3 PCA3 can be detected in urine from patients with prostate cancer [5]. Though Metastasis associated lung adenocarcinoma transcript 1 (MALAT-1) is first found abnormal expressed in metastasizing non-small-cell lung carcinomas [6], it is up-regulated in hepatocarcinoma, breast cancer, pancreatic cancer, colorectal cancer, and prostate cancer [7].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA expression profile in human gastric cancer and its clinical significances

et al. 2013

View full text Add to dashboard Cite

BackgroundLong non-coding RNAs (lncRNAs) are prevalently transcribed in the genome yet their potential roles in human cancers are not well understood. The aim of the present study was to determine the lncRNA expression profile in gastric cancer and its potential clinical value.MethodsThe global lncRNA expression profile in gastric cancer was measured by lncRNA microarray. Levels of two representative lncRNAs, H19 and uc001lsz, were confirmed by real-time reverse transcriptase-polymerase chain reaction. The relationship between their levels and clinicopathological factors of patients with gastric cancer was explored. A receiver operating characteristic (ROC) curve was constructed for differentiating gastric cancer from benign gastric diseases.ResultsTotal of 135 lncRNAs, which differential expression levels between tumor and non-tumorous tissues were more than twofold, were found (GEO No. GSE47850). The most down-regulated lncRNAs in gastric cancer tissues were FER1L4, uc001lsz, BG491697, AF131784, uc009ycs, BG981369, AF147447, HMlincRNA1600, and AK054588; while the most up-regulated ones were H19, HMlincRNA717, BM709340, BQ213083, AK054978, and DB077273. H19 was found highly expressed in stomach and liver cancer cell lines, while lowly expressed in lung cancer and prostate cancer cell lines. Uc001lsz was lowly expressed in gastric, lung and liver cancer cell lines, while highly expressed in prostate cancer. The areas under ROC curves were up to 0.613, 0.751, and 0.761 for H19, uc001lsz, and the combination, respectively.ConclusionsThe lncRNA expression profile in gastric cancer suggests the potential roles of lncRNAs in gastric cancer occurrence and development. The overexpression of H19 in gastric cancer suggests that H19 may be participated in gastric cancer. The reduced expression of uc001lsz in gastric cancer cell lines and tissues, its associations with TNM stage, and its dysregulation in early cancer and precancerous lesions suggest that uc001lsz may be a potential marker for the diagnosis of early gastric cancer.

show abstract

“…The most frequently used CaP screening marker—prostate specific antigen (PSA) is organ specific but cannot specify the stage and the type of disease, so its use for prostate cancer screening is insufficient [12]. Therefore, nowadays prostatic antigen 3 (PCA 3) [13–15] and annexin (A3) [5,16–18] are the most widely used and generally accepted markers of non-invasive CaP in urine. There are also other newly discussed potential markers of CaP that may be useful in the diagnosis of progression of prostate cancer, which can be detected in urine, such as alpha-methylacyl-CoA racemase (AMACR) [19–21], which level is elevated in prostatic adenocarcinoma and high-grade intraepithelial neoplasia.…”

Section: Introductionmentioning

confidence: 99%

Sarcosine as a Potential Prostate Cancer Biomarker—A Review

Cernei

Heger

Gumulec

et al. 2013

IJMS

111

View full text Add to dashboard Cite

Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.

show abstract

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population

Cited by 26 publications

References 13 publications

East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians

East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians

Long non-coding RNA expression profile in human gastric cancer and its clinical significances

Sarcosine as a Potential Prostate Cancer Biomarker—A Review

Contact Info

Product

Resources

About